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The aim of this study was to clarify the factors associated with the remission and/or regression of 
microalbuminuria in Japanese patients with type 2 diabetes mellitus.  We retrospectively analyzed the 
data of 130 patients with type 2 diabetes mellitus with microalbuminuria for 2-6 years (3.39±1.31 
years).  Remission was deﬁned as improving from microalbuminuria to normoalbuminuria using the 
albumin/creatinine ratio (ACR),  and regression of microalbuminuria was deﬁned as a decrease in 
ACR of 50ｵ or more from baseline.  Progression of microalbuminuria was deﬁned as progressing 
from microalbuminuria to overt proteinuria during the follow-up period.  Among 130 patients with 
type 2 diabetes mellitus with microalbuminuria,  57 and 13 patients were deﬁned as having remission 
and regression,  respectively,  while 26 patients progressed to overt proteinuria.  Sex (female),  higher 
HDL cholesterol and lower HbA1c were determinant factors associated with remission/regression of 
microalbuminuria by logistic regression analysis.  Lower systolic blood pressure (SBP) was also cor-
related with remission/regression,  but not at a signiﬁcant level.  These results suggest that proper 
control of blood glucose,  BP and lipid proﬁles may be associated with remission and/or regression of 
type 2 diabetes mellitus with microalbuminuria in clinical practice.
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he number of diabetes mellitus patients is dra-
matically increasing in Japan and has become 
public health challenge.  It is well known that diabetic 
nephropathy is one of the most serious complications 
of diabetes mellitus.  More than 300,000 patients in 
Japan undergo hemodialysis,  and about 44ｵ of those 
just starting hemodialysis in 2012 were aﬀected by 
diabetes mellitus [1].  In addition,  diabetic nephropa-
thy is an independent risk factor for cardiovascular 
disease,  and has a serious impact on quality of life and 
health care costs [2-7].  The earliest known manifes-
tation of diabetic nephropathy is the presence of small 
amounts of albumin in the urine,  called microalbu-
minuria [8].  In our country,  more than 40ｵ of 
patients with type 2 diabetes mellitus have microalbu-
minuria [9].  Recommended treatment of diabetic 
nephropathy is as follows: 1) tight control of blood 
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glucose,  2) tight control of blood pressure (BP),  3) 
suppression of the renin-angiotensin system (RAS) 
using angiotensin-converting-enzyme (ACE) inhibitors 
or angiotensin-receptor blockers (ARBs),  4) control of 
lipid proﬁles,  5) diet therapy,  and 6) lifestyle modiﬁ-
cation (including smoking cessation) [9].  In patients 
with type 2 diabetes mellitus,  the course of renal 
dysfunction is more heterogeneous,  and the natural 
progression less well characterized than in patients 
with type 1 diabetic nephropathy [10].  Furthermore,  
for a wide variety of treatment methods,  the impact of 
each treatment on preventing and improving diabetic 
nephropathy in patients with type 2 diabetes mellitus 
has not been fully examined in clinical practice.
　 In the present study,  we evaluated the remission/
regression vs. progression of microalbuminuria in 
Japanese patients with type 2 diabetes mellitus in a 
single clinical practice.  In addition,  we clariﬁed the 
factors that are associated with remission and/or 
regression of microalbuminuria.
Subjects and Methods
　 Subjects. We retrospectively collected the data 
of 130 subjects who met the following criteria: (1) 
diagnosed as having type 2 diabetes mellitus in accor-
dance with the criteria of the Japanese Diabetes 
Society [11] and the World Health Organization [12] 
at the Department of Medicine,  Okayama University 
Hospital between January 2006 and December 2009;  
(2) having microalbuminuria by at least 2 measure-
ments of albumin/creatinine ratio (ACR) in a spot 
urine sample,  and their diabetic nephropathy status 
was determined; (3) having no complicating cancer,  
liver disease,  collagen disease,  or nondiabetic kidney 
disease conﬁrmed by renal biopsy; and (4) having 
received follow-up physical examinations at least every 
two months,  while undergoing measurements of ACR 
in a spot urine sample at least once a year for 2-6 
years.
　 All participants received treatment based on the 
standard strategies for diabetes mellitus,  hyperten-
sion,  and dyslipidemia during these periods.
　 This study was approved by the Ethics Committee 
on Epidemiological Studies of Okayama University 
Graduate School of Medicine,  Dentistry and Pharma-
ceutical Sciences.
　 Assessment of urinary albumin excretion.
The albumin excretion rate was estimated on the basis 
of the ACR in spot urine samples,  as previously 
described [13-15].  The levels of albumin excreted in 
each measurement of ACR were classiﬁed as normoal-
buminuria (ACR＜30mg/g creatinine),  microalbu-
minuria (30ｦACR＜300mg/g creatinine),  and overt 
proteinuria (ACRｧ300mg/g creatinine).
　 Criteria for remission, regression and pro-
gression of microalbuminuria. We applied the 
criteria of previous reports for remission,  regression 
and progression of microalbuminuria [16,  17].  Remis-
sion of microalbuminuria was deﬁned as returning to 
normoalbuminuria during the follow-up period; regres-
sion of microalbuminuria was deﬁned as a decrease in 
ACR of 50ｵ or more from baseline.  Otherwise,  
progression of microalbuminuria was deﬁned as pro-
gressing from microalbuminuria to overt proteinuria 
during the follow-up period.
　 Clinical parameters. All data were retrospec-
tively obtained from electronic charts.  Body mass 
index (BMI) was the weight in kilograms divided by 
the square of the height in meters.  The estimated 
Glomerular Filtration Rate (eGFR) was calculated 
using the following equation: eGFR (ml/min/1.73m2)
＝194×Cr-1.094×Age-0.287×0.739 (a constant derived 
speciﬁcally for women) [18].  Among antihypertensive 
drugs,  RAS blockade drugs including ACE inhibitors 
or ARBs and other antihypertensive drugs were sepa-
rately recorded and analyzed.
　 Statistical analysis. Values are expressed as 
means ± standard deviations (SDs) for continuous 
variables.  The participants were classiﬁed by the 
course of microalbuminuria,  remission and/or regres-
sion,  no change and progression.  One-way analysis of 
variance (ANOVA) and Tukeyʼs F test were used to 
compare among 3 groups.  Participants were also clas-
siﬁed as being with or without remission/regression 
of microalbuminuria during the follow-up period.  
Comparisons between these 2 groups was performed 
using Chi-squared tests for categorical variables and 
unpaired t tests for continuous variables.  Univariate 
and multivariate analyses were also performed using a 
logistic regression model.
　 To investigate the importance of each clinical 
practice recommendation,  we dichotomized the levels 
of HbA1c,  BP,  and lipid proﬁles as salutary or non-
salutary.  The salutary levels were deﬁned as follows:  
HbA1c＜6.5ｵ,  BP＜130/80mmHg,  and lipid proﬁles 
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＜150mg/dl for triglycerides,  ＜120mg/dl for LDL 
cholesterol,  and ｧ40mg/dl for HDL cholesterol,  
according to the clinical practice recommendations of 
the Japanese Diabetes Society [19].  We then coded 
each follow-up period of observation on a scale from 0 
to 3 according to the number of the 3 factors with a 
salutary level,  and calculated hazard ratios.
　 All statistical analyses were performed using the 
SPSS 21.0 software program for Windows.  We 
selected p values ＜0.05 as the threshold of statistical 
signiﬁcance in all tests.
Results
　 During the follow-up period (average of 3.4 years),  
among 130 type-2 diabetes mellitus patients with 
microalbuminuria,  57 patients (43.8ｵ) demonstrated 
remission of microalbuminuria,  13 patients (10.0ｵ) 
demonstrated regression of microalbuminuria,  and 26 
patients (20.0ｵ) progressed to overt proteinuria.  The 
remission/regression rate was higher than that of 
progression.
　 The clinical characteristics of the patients at base-
line according to the course of microalbuminuria are 
summarized in Table 1.  Among participants with 
remission and/or regression of microalbuminuria,  the 
proportions of males and alcohol drinkers were sig-
niﬁcantly lower than those in other categories.  In 
participants with progression of microalbuminuria,  
systolic BP,  ACR and diabetic retinopathy were sig-
niﬁcantly higher than those in other participants.  In 
participants with remission/regression of microalbu-
minuria,  HDL cholesterol was signiﬁcantly higher 
than that in participants with progression of microal-
buminuria.
　 Next,  we compared the clinical characteristics 
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Table 1　 Clinical characteristics of the study participants at baseline according to the course of microalbuminuria
Remission and/or Regression No change Progression
Number of participants: n (%) 70 (53.8) 34 (26.2) 26 (20.0)
Male sex: n (%) 30 (42.9)ab 24 (70.6) 20 (76.9)
Age (years) 59.9±14.3 62.0±13.8 64.3±11.5
Duration of diabetes (years) 9.6±7.9 10.7±10.1 14.2±11.2
Current smoking: n (%) 16 (27.6) 8 (27.6) 12 (50.5)
Alcohol drinker: n (%) 12 (20.7)ab 15 (50.0) 11 (45.8)
Body mass index (kg/m2) 25.3±4.5 25.7±4.7 24.6±4.1
Systolic blood pressure (mmHg) 128.9±14.7b 132.1±11.4b 141.2±15.9
Diastolic blood pressure (mmHg) 74.7±9.5 74.9±11.6 79.0±12.4
HbA1c (%) 7.5±1.4 7.4±1.0 7.7±1.5
Plasma glucose (mg/dl) 168.0±58.1 181.5±60.2 178.2±49.6
BUN (mg/dl) 17.2±8.5 17.2±6.6 18.3±4.9
Serum creatinine (mg/dl) 0.81±0.73 0.86±0.25 0.88±0.32
Estimated Glomerular Filtration Rate (ml/min/1.73m2) 79.6±28.0 70.1±20.3 71.8±25.2
ACR (mg/g creatinine) 69.6±61.6b 79.0±73.9b 152.9±107.2
Uric acid (mg/dl) 5.2±2.0 5.6±1.4 5.5±1.4
Total cholesterol (mg/dl) 198.0±34.1 204.7±31.8 184.1±38.9
Triglycerides (mg/dl) 147.4±90.7 178.9±113.7 158.9±157.8
HDL cholesterol (mg/dl) 60.1±15.9b 54.0±16.1 50.4±12.6
LDL cholesterol (mg/dl) 111.7±28.6 117.3±29.6 103.9±24.9
Diabetic neuropathy: n (%) 26 (39.4) 13 (40.6) 15 (60.0)
Diabetic retinopathy: n (%) 23 (33.8)b 8 (25.8)b 16 (61.5)
IHD: n (%) 8 (11.4) 4 (11.8) 4 (15.4)
CVD: n (%) 3 (4.3) 2 (5.9) 2 (7.7)
PAD: n (%) 2 (2.9) 2 (5.9) 1 (3.8)
Use of ACE inhibitor or ARBs: n (%) 30 (42.9) 18 (52.9) 16 (61.5)
Use of Statin: n (%) 20 (28.6) 12 (35.5) 6 (23.1)
Data are means ± SD unless otherwise indicated.  IHD,  ischemic heart disease.  CVD,  cerebral vascular disorder.  PAD,  peripheral arte-
rial disease.
ap＜0.05 versus no change.  bp＜0.05 versus progression.
between patients with and without remission/regres-
sion in the follow-up period.  In the univariate analysis,  
signiﬁcant diﬀerences of plasma glucose,  HbA1c,  
creatinine and BUN were noted between the 2 groups 
(Table 2).  To adjust for confounding factors such as 
duration of diabetes,  total cholesterol and smoking 
habits by logistic regression analysis,  we found that 
the female sex [odds ratio (OR): 4.34,  (95ｵ conﬁ-
dence interval (CI): 1.70-11.12),  p＝0.002],  higher 
HDL cholesterol (ｧ50mg/dl) [OR: 3.65,  (95ｵ CI:  
1.06-9.88),  p＝0.031] and lower HbA1c (ｦ6.0ｵ) 
[OR: 5.61,  (95ｵ CI: 1.13-27.85),  p＝0.035] were 
independently associated with remission/regression of 
microalbuminuria (Table 3),  whereas lower SBP 
(ｦ130mmHg) [OR: 2.66,  (95ｵ CI: 0.83-7.23),  p＝
0.122] was weakly associated with remission/regres-
sion of microalbuminuria,  i.e.,  not at a signiﬁcant 
level.
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Table 2　 Clinical characteristics of the study participants at follow-up according to the presence or absence of remission and/or regres-
sion of microalbuminuria
Remission and/or Regression No Remission and/or Regression p value
Mean follow-up time (years) 2.8±1.1 4.1±1.6 ＜0.001＊
Body mass index (kg/m2) 25.4±4.3 25.3±4.4 0.893
Systolic blood pressure (mmHg) 129.3±11.6 131.1±12.0 0.398
Diastolic blood pressure (mmHg) 73.6±9.1 73.6±11.0 0.991
HbA1c (%) 6.7±0.8 7.2±1.2 0.023＊
Plasma glucose (mg/dl) 151.1±32.2 168.8±52.4 0.028＊
BUN (mg/dl) 16.3±4.6 18.7±6.4 0.020＊
Serum creatinine (mg/dl) 0.75±0.20 0.91±0.29 ＜0.001＊
Estimated Glomerular Filtration Rate (ml/min/1.73m2) 71.4±21.2 64.9±19.7 0.079
Uric acid (mg/dl) 5.4±1.3 5.7±1.3 0.215
Total cholesterol (mg/dl) 190.5±25.1 192.2±43.3 0.793
Triglycerides (mg/dl) 134.9±71.4 161.0±117.9 0.131
HDL cholesterol (mg/dl) 55.6±14.7 51.6±12.8 0.117
LDL cholesterol (mg/dl) 109.5±19.9 105.2±22.1 0.254
Use of ACE inhibitor or ARBs: n (%) 39 (55.7) 41 (68.3) 0.153
Use of Statin: n (%) 24 (34.3) 31 (51.7) 0.074
Data are means ± SD unless otherwise indicated.  ＊p＜0.05.
Table 3　 The ORs of factors associated with the remisson and/or regression of microalbuminuria with the logistic regrsssion model
Factor Adjusted odds ratio 95% conﬁdence interval p value
Sex (female) 4.34 1.70-11.12 0.002＊
HDL cholesterol (mg/dl) 0.031＊
　　　HDL＜40 1 ref.
　　　40ｦHDL＜50 1.10 0.23-3.06
　　　50ｦHDL＜60 3.65 1.06-9.88
　　　60ｦHDL 4.17 1.20-11.53
HbA1c (%) 0.035＊
　　　7.0＜HbA1c 1 ref.
　　　6.5＜HbA1cｦ7.0 3.53 0.67-18.63
　　　6.0＜HbA1cｦ6.5 4.26 0.83-21.92
　　　HbA1cｦ6.0 5.61 1.13-27.85
Systolic blood pressure (mmHg) 0.122　
　　　140＜SBP 1 ref.
　　　130＜SBPｦ140 1.42 0.51-3.76
　　　SBPｦ130 2.66 0.83-7.23
The multivariate model was adjusted for BMI,  duration of diabetes,  total cholesterol,  smoking habits,  and use of ACE inhibitor or ARBs.
Ref.,  reference category.  ＊p＜0.05.
　 Finally,  the clinical importance of recommended 
guidelines for glycemic exposure,  BP and lipid pro-
ﬁles was evaluated by the multivariate model adjusted 
for sex and use of ACE inhibitor or ARBs.  The haz-
ard ratio for the remission/regression of microalbu-
minuria increased with each increment in the number 
of factors at a salutary level (Fig.  1),  when 3 factors,  
as compared with none,  were at the salutary levels,  
the hazard ratio for remission/regression of microal-
buminuria was 1.489 (95ｵ CI: 0.625-3.550),  but not 
at a signiﬁcant level.
Discussion
　 Microalbuminuria in patients with type 2 diabetes 
mellitus has been considered the ﬁrst step toward 
overt proteinuria and renal failure.  However,  our 
results indicate that microalbuminuria can improve to 
normal levels in some Japanese type 2 diabetes melli-
tus patients.  Among 130 patients with microalbuminu-
ria,  only 20ｵ of patients progressed to overt protei-
nuria,  whereas 40ｵ of patients improved to 
normoalbuminuria.
　 This study also provided evidence that rigorous 
control of glycemic exposure,  HDL cholesterol and 
SBP,  and female sex were independently associated 
with the remission and/or regression of microalbu-
minuria.  Improvement of microalbuminuria has recently 
been reported in patients with type 1 and type 2 dia-
betes mellitus.  Perkins et al.  found frequent regres-
sion,  with 58ｵ (95ｵ CI: 52-64) incidence at the 
6-year follow-up in patients with type 1 diabetes mel-
litus [16].  Araki et al.  also found frequent remission 
and/or regression,  with ～50ｵ incidence at the 
6-year follow-up in patients with type 2 diabetes mel-
litus [17].  These observations strongly indicate that 
microalbuminuria frequently regresses,  contrary to 
our expectations.  In this study,  we additionally iden-
tiﬁed the factors associated with the reduction of 
microalbuminuria in type 2 diabetes mellitus.
　 The level of blood glucose seems to be the stron-
gest factor inﬂuencing the onset of microalbuminuria.  
This has been demonstrated in several observational 
studies [13,  14,  20-23] as well as in clinical trials 
[24-27].  In our study,  the lower HbA1c (ｦ6.0ｵ) 
was independently associated with remission/regres-
sion of microalbuminuria.  This cutoﬀ value is lower 
than the recommended therapeutic target (＜7.0ｵ) 
for HbA1c [19,  28].  Additionally,  the Steno type 2 
randomized study [29] showed that the target HbA1c 
level to prevent progression of diabetic nephropathy 
was ＜6.5ｵ.  In our study,  the ORs for remission/
regression of microalbuminuria in subjects with 
HbA1c＜7.0ｵ was not statistically signiﬁcant (OR:  
3.68,  95ｵ conﬁdence interval: 0.71-17.33).  Our 
participantsʼ mean HbA1c at baseline (7.2±1.0ｵ) was 
lower than in other previous studies.
　 Essential hypertension [30-33],  elevated SBP 
[23,  32],  cigarette smoking [14,  34],  elevated lev-
els of serum cholesterol and triglycerides [22],  and 
genetic susceptibility are risk factors for diabetic 
nephropathy [35].  Maintaining BP ＜130/80mmHg 
is recommended in diabetic patients for preservation 
of renal function and reduction of cardiovascular events 
[19,  28,  36].  In our study,  lower SBP (ｦ130mmHg) 
and lower DBP (ｦ80mmHg) were not independently 
associated with remission/regression of microalbu-
minuria because our participantsʼ mean SBP and DBP 
at baseline (130.6±10.8mmHg,  75.3±8.5mmHg) were 
comparably well controlled.  In lipid proﬁles,  HDL 
cholesterol was independently associated with 
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Fig. 1　 Additive eﬀects of factors at salutary levels on remission 
and/or regression of microalbuminuria.  Salutary levels of the vari-
ous factors were deﬁned as＜6.5% for HbA1c,  a combination of 
＜130mmHg of systolic blood pressure and＜80mmHg of diastolic 
blood pressure, and a combination of＜150mg/dl of triglyceride,  
＜120mg/dl of LDL cholesterol,  andｧ40mg/dl of HDL choles-
terol.  The reference category was considered to be the absence of 
a salutary level for any of the 3 factors.  The estimates were 
adjusted for sex,  and use of ACE inhibitor or ARBs.  The number of 
patients having 0,  1,  2,  and 3 factors at salutary levels were 23 
(18.1%),  47 (37.0%),  40 (31.5%),  and 17 (13.4%),  respectively.
improvement of microalbuminuria.  We thought that 
LDL cholesterol might not have been statistically 
signiﬁcant in our study because LDL cholesterol was 
well controlled by the use of statins,  especially in 
participants with progression of microalbuminuria.  
These results suggest that normalization of the lipid 
proﬁle may be associated with remission/regression of 
type 2 diabetes mellitus with microalbuminuria.
　 Sex is one of the risk factors for microvascular 
complications,  as well as blood glucose,  BP,  lipids 
and cigarette smoking.  However,  there have been few 
reports relating sex to the incidence/prevalence and 
the pathological condition of microvascular complica-
tions.  There have been a few studies regarding sex as 
a risk factor for nephropathy,  with diﬀerent results.  
In a German study of type 1 diabetes mellitus patients,  
male sex was a risk factor for evident nephropathy 
[37].  In a study of UKPDS,  male sex was a risk 
factor of an evident albumin urocrisis [38].  In the 
report of Takane et al.,  the time when diabetes melli-
tus and nephropathy were diagnosed tended to be 
earlier in men than in women,  and the dialysis induc-
tion age was signiﬁcantly lower in men [39].  Daniels 
et al.  showed that female sex associated with an 
increased frequency of microalbuminuria in children 
and adolescents with type 1 diabetes mellitus [40].  In 
this study,  the rate of remission/regression of 
microalbuminuria was signiﬁcantly higher in female 
patients.  Future studies investigating sex-speciﬁc 
interventions to reduce the incidence and rate of pro-
gression of diabetic nephropathy are required.
　 Potential limitations still remain in our study.  
First,  the deﬁnition of regression of microalbuminu-
ria is not generally recognized.  We deﬁned regression 
of microalbuminuria as a decrease in ACR of ｧ50ｵ 
from baseline,  as in the Joslin Diabetes Center study 
and Shiga University study [16,  17].  This deﬁnition 
does not always reﬂect changes in renal function.  It 
remains unclear whether a decrease in ACR of ｧ50 
percent reﬂects improvements in morphological abnor-
malities.  Second,  our study did not clarify whether 
remission and/or regression of microalbuminuria 
ﬁnally results in a reduction of the incidence of end-
stage renal disease (ESRD) or cardiovascular mortal-
ity.  Because the average observation period was 
short,  continuation of the observation over the long 
term is necessary to conﬁrm the results.  Third,  we 
examined biochemical measurements in spot blood 
samples,  so blood glucose and triglycerides were not 
evaluated.  Fourth,  the small sample size made it dif-
ﬁcult to prove the factors that are associated with 
remission/regression of microalbuminuria,  or to 
investigate the importance of each clinical practice 
recommendation separately.
　 In conclusion,  we revealed the conditions for 
improvement of microalbuminuria in patients with type 
2 diabetes mellitus at a typical Japanese clinic.  These 
results suggest that management of blood glucose and 
BP are beneﬁcial and useful measures for the remis-
sion and/or regression of microalbuminuria.  Lipid 
proﬁles,  especially higher level of HDL cholesterol,  
might also be important for remission/regression of 
microalbuminuria.  In addition,  the possibility of sex-
speciﬁc interventions to reduce the incidence and rate 
of progression of diabetic nephropathy was suggested.
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